Logo image of 1EXEL.MI

EXELIXIS INC (1EXEL.MI) Stock Fundamental Analysis

BIT:1EXEL - US30161Q1040 - Common Stock

32.88 EUR
-3.08 (-8.57%)
Last: 8/21/2025, 7:00:00 PM
Fundamental Rating

8

1EXEL gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making 1EXEL a very profitable company, without any liquidiy or solvency issues. An interesting combination arises when we look at growth and value: 1EXEL is growing strongly while it also seems undervalued. With these ratings, 1EXEL could be worth investigating further for value and growth and quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year 1EXEL was profitable.
In the past year 1EXEL had a positive cash flow from operations.
Each year in the past 5 years 1EXEL has been profitable.
In the past 5 years 1EXEL always reported a positive cash flow from operatings.
1EXEL.MI Yearly Net Income VS EBIT VS OCF VS FCF1EXEL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

With an excellent Return On Assets value of 22.68%, 1EXEL belongs to the best of the industry, outperforming 91.78% of the companies in the same industry.
1EXEL has a better Return On Equity (30.20%) than 94.52% of its industry peers.
1EXEL has a better Return On Invested Capital (26.25%) than 98.63% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1EXEL is below the industry average of 13.68%.
The 3 year average ROIC (10.78%) for 1EXEL is below the current ROIC(26.25%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 22.68%
ROE 30.2%
ROIC 26.25%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1EXEL.MI Yearly ROA, ROE, ROIC1EXEL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 150

1.3 Margins

The Profit Margin of 1EXEL (27.99%) is better than 89.04% of its industry peers.
In the last couple of years the Profit Margin of 1EXEL has declined.
With an excellent Operating Margin value of 35.43%, 1EXEL belongs to the best of the industry, outperforming 89.04% of the companies in the same industry.
In the last couple of years the Operating Margin of 1EXEL has declined.
Looking at the Gross Margin, with a value of 96.78%, 1EXEL belongs to the top of the industry, outperforming 93.15% of the companies in the same industry.
1EXEL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 35.43%
PM (TTM) 27.99%
GM 96.78%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
1EXEL.MI Yearly Profit, Operating, Gross Margins1EXEL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1EXEL is creating value.
Compared to 1 year ago, 1EXEL has less shares outstanding
The number of shares outstanding for 1EXEL has been reduced compared to 5 years ago.
1EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
1EXEL.MI Yearly Shares Outstanding1EXEL.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
1EXEL.MI Yearly Total Debt VS Total Assets1EXEL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

1EXEL has an Altman-Z score of 10.98. This indicates that 1EXEL is financially healthy and has little risk of bankruptcy at the moment.
1EXEL has a better Altman-Z score (10.98) than 89.04% of its industry peers.
1EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 10.98
ROIC/WACC2.7
WACC9.72%
1EXEL.MI Yearly LT Debt VS Equity VS FCF1EXEL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 3.50 indicates that 1EXEL has no problem at all paying its short term obligations.
1EXEL has a Current ratio of 3.50. This is in the better half of the industry: 1EXEL outperforms 68.49% of its industry peers.
A Quick Ratio of 3.44 indicates that 1EXEL has no problem at all paying its short term obligations.
The Quick ratio of 1EXEL (3.44) is better than 67.12% of its industry peers.
Industry RankSector Rank
Current Ratio 3.5
Quick Ratio 3.44
1EXEL.MI Yearly Current Assets VS Current Liabilites1EXEL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 205.56% over the past year.
Measured over the past years, 1EXEL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.65% on average per year.
Looking at the last year, 1EXEL shows a very strong growth in Revenue. The Revenue has grown by 24.50%.
1EXEL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.51% yearly.
EPS 1Y (TTM)205.56%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%175%
Revenue 1Y (TTM)24.5%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%30.62%

3.2 Future

Based on estimates for the next years, 1EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 24.67% on average per year.
Based on estimates for the next years, 1EXEL will show a quite strong growth in Revenue. The Revenue will grow by 10.68% on average per year.
EPS Next Y23.6%
EPS Next 2Y19.76%
EPS Next 3Y22.02%
EPS Next 5Y24.67%
Revenue Next Year7.43%
Revenue Next 2Y9.22%
Revenue Next 3Y11.04%
Revenue Next 5Y10.68%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
1EXEL.MI Yearly Revenue VS Estimates1EXEL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
1EXEL.MI Yearly EPS VS Estimates1EXEL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 17.40, which indicates a rather expensive current valuation of 1EXEL.
Compared to the rest of the industry, the Price/Earnings ratio of 1EXEL indicates a rather cheap valuation: 1EXEL is cheaper than 84.93% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of 1EXEL to the average of the S&P500 Index (27.14), we can say 1EXEL is valued slightly cheaper.
A Price/Forward Earnings ratio of 14.45 indicates a correct valuation of 1EXEL.
Based on the Price/Forward Earnings ratio, 1EXEL is valued cheaper than 86.30% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of 1EXEL to the average of the S&P500 Index (22.80), we can say 1EXEL is valued slightly cheaper.
Industry RankSector Rank
PE 17.4
Fwd PE 14.45
1EXEL.MI Price Earnings VS Forward Price Earnings1EXEL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, 1EXEL is valued cheaper than 84.93% of the companies in the same industry.
87.67% of the companies in the same industry are more expensive than 1EXEL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 12.73
EV/EBITDA 10.15
1EXEL.MI Per share data1EXEL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of 1EXEL may justify a higher PE ratio.
A more expensive valuation may be justified as 1EXEL's earnings are expected to grow with 22.02% in the coming years.
PEG (NY)0.74
PEG (5Y)1.38
EPS Next 2Y19.76%
EPS Next 3Y22.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 1EXEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXELIXIS INC

BIT:1EXEL (8/21/2025, 7:00:00 PM)

32.88

-3.08 (-8.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners94.07%
Inst Owner ChangeN/A
Ins Owners2.2%
Ins Owner ChangeN/A
Market Cap8.97B
Analysts76.92
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.83%
Min EPS beat(2)10.66%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)55.5%
Min EPS beat(4)10.66%
Max EPS beat(4)148.98%
EPS beat(8)6
Avg EPS beat(8)22.76%
EPS beat(12)9
Avg EPS beat(12)18.75%
EPS beat(16)12
Avg EPS beat(16)61.89%
Revenue beat(2)1
Avg Revenue beat(2)3.96%
Min Revenue beat(2)-1.38%
Max Revenue beat(2)9.31%
Revenue beat(4)3
Avg Revenue beat(4)12.55%
Min Revenue beat(4)-1.38%
Max Revenue beat(4)34.34%
Revenue beat(8)4
Avg Revenue beat(8)4.97%
Revenue beat(12)6
Avg Revenue beat(12)3.28%
Revenue beat(16)8
Avg Revenue beat(16)4.82%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 17.4
Fwd PE 14.45
P/S 4.55
P/FCF 12.73
P/OCF 12.4
P/B 4.9
P/tB 5.06
EV/EBITDA 10.15
EPS(TTM)1.89
EY5.75%
EPS(NY)2.28
Fwd EY6.92%
FCF(TTM)2.58
FCFY7.85%
OCF(TTM)2.65
OCFY8.06%
SpS7.23
BVpS6.7
TBVpS6.5
PEG (NY)0.74
PEG (5Y)1.38
Profitability
Industry RankSector Rank
ROA 22.68%
ROE 30.2%
ROCE 33.41%
ROIC 26.25%
ROICexc 45.49%
ROICexgc 47.65%
OM 35.43%
PM (TTM) 27.99%
GM 96.78%
FCFM 35.71%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexcg growth 3Y9.55%
ROICexcg growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score9
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 72.88%
Cap/Sales 0.94%
Interest Coverage 250
Cash Conversion 99.8%
Profit Quality 127.55%
Current Ratio 3.5
Quick Ratio 3.44
Altman-Z 10.98
F-Score9
WACC9.72%
ROIC/WACC2.7
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)205.56%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%175%
EPS Next Y23.6%
EPS Next 2Y19.76%
EPS Next 3Y22.02%
EPS Next 5Y24.67%
Revenue 1Y (TTM)24.5%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%30.62%
Revenue Next Year7.43%
Revenue Next 2Y9.22%
Revenue Next 3Y11.04%
Revenue Next 5Y10.68%
EBIT growth 1Y298.52%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year34.7%
EBIT Next 3Y31.16%
EBIT Next 5YN/A
FCF growth 1Y209.54%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y181.52%
OCF growth 3Y20.43%
OCF growth 5Y5.84%